Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Total Current Liabilities (2019 - 2025)

Allogene Therapeutics' Total Current Liabilities history spans 7 years, with the latest figure at $31.8 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 2.27% year-over-year to $31.8 million; the TTM value through Sep 2025 reached $31.8 million, down 2.27%, while the annual FY2024 figure was $35.5 million, 4.2% down from the prior year.
  • Total Current Liabilities for Q3 2025 was $31.8 million at Allogene Therapeutics, roughly flat from $31.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $59.6 million in Q1 2023 and bottomed at $30.0 million in Q1 2025.
  • The 5-year median for Total Current Liabilities is $37.5 million (2023), against an average of $42.4 million.
  • The largest YoY upside for Total Current Liabilities was 104.52% in 2021 against a maximum downside of 49.21% in 2021.
  • A 5-year view of Total Current Liabilities shows it stood at $47.9 million in 2021, then increased by 13.8% to $54.5 million in 2022, then plummeted by 31.99% to $37.1 million in 2023, then dropped by 4.2% to $35.5 million in 2024, then decreased by 10.39% to $31.8 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Total Current Liabilities are $31.8 million (Q3 2025), $31.7 million (Q2 2025), and $30.0 million (Q1 2025).